Democrats in Disarray over Socialist Drug Pricing Scheme
Democrats cannot come to a consensus over whether or not to socialize drug pricing. H.R. 3, the Higher Costs and Fewer Cures Act, is packaged into the radical fiscal year 2022 budget and would allow the Secretary of Health and Human Services to mandate private companies’ drug prices or face a bankruptcy-inducing 95 percent tax rate. It’s government interference in the dealings of private companies... Read more »